Quantum Brilliance: reimagining drug discovery with quantum computing

The discovery and design of novel therapies is an increasingly challenging endeavour in the 21st century; though technology has progressed in leaps and bounds, identifying previously unknown molecules and drugs has become trickier, and every avenue that could accelerate or enhance the process must be explored. Approaches that were once unthinkable, such as artificial intelligence, have become commonplace in drug discovery – and now, quantum computing is emerging as pharma’s next frontier.

Antibiotic resistance: how AI can tackle the superbug threat

As the world continues to grapple with the Covid-19 pandemic, another health crisis is looming: antibiotic resistance. Bacterial resistance is something that occurs naturally, but widespread antibiotic misuse has propelled antimicrobial resistance (AMR) to major global health threat status; at least 700,000 people are killed by drug-resistant superbugs every year – and by 2050, this number could reach 10 million.

Are supercomputers set to transform pharma R&D?

Advanced technology is now commonplace in pharma, where innovations like artificial intelligence (AI) and machine learning accelerate and improve the accuracy of drug discovery and development efforts. Add to the list the supercomputer – a powerful class of computer, vastly superior to general-purpose computers in terms of speed and performance, that are commonly used for data-intensive scientific purposes.